why choose us

First received: August 17, 2022

Clinical Trial: Biomarker Analysis of Anti-PD-1 Antibody Combined With Chemotherapy for Neoadjuvant Treatment of Locally Advanced GC

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Locally Advanced Gastric Adenocarcinoma
PD-1

Study Type: Observational


Official Title: Predictive Biomarker Analysis and Model Construction of PD-1 Monoclonal Antibody Combined With Chemotherapy for Neoadjuvant Treatment of Locally Advanced Gastric Cancer: A Single-center, Observational

Brief Summary: Gastric cancer is one of the most common malignant tumors in China, ranking the fifth highest incidence and third highest mortality worldwide. Currently, surgical resection is the preferred treatment for gastric cancer, while the 5-year survival rate of patients is lower than 25%. Compared with surgical resection, immunotherapy is proved to be able to effectively prolong the survival time of patients. On one hand, with the continuous promotion of immunotherapy drugs, the exploration of neoadjuvant application of…

Read more